Last reviewed · How we verify
Gynorest (DYDROGESTERONE)
At a glance
| Generic name | DYDROGESTERONE |
|---|---|
| Sponsor | Solvay |
| Drug class | dydrogesterone |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Luteal phase support
- Prevention of premature ovulation during controlled ovarian stimulation
Common side effects
Key clinical trials
- Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy (NA)
- PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study) (NA)
- Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study
- A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion (NA)
- Clinical Study on the Effect of Umbilical Cord Mesenchymal Stem Cell Exosomes on Endometrial Repair of Intrauterine Adhesions (NA)
- IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols (NA)
- Multifaceted Benefits of Auricular Point Sticking for IVF Patients: Psychological Well-being, Sleep, and Treatment Outcomes (NA)
- rFSH vs rFSH+rLH in Dydrogesterone-Based Progestin Protocol: A Prospective Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gynorest CI brief — competitive landscape report
- Gynorest updates RSS · CI watch RSS
- Solvay portfolio CI